A Pilot Study Exploring the Association of Entacapone, Gut Microbiota, and the Subsequent Side Effects in Patients With Parkinson's Disease/Experiment 1
Subjects
- Location of subjects
- China
- Host species Species from which microbiome was sampled. Contact us to have more species added.
- Homo sapiens
- Body site Anatomical site where microbial samples were extracted from according to the Uber Anatomy Ontology
- Feces Cow dung,Cow pat,Droppings,Dung,Excrement,Excreta,Faeces,Fecal material,Fecal matter,Fewmet,Frass,Guano,Matières fécales@fr,Merde@fr,Ordure,Partie de la merde@fr,Piece of shit,Porción de mierda@es,Portion of dung,Portion of excrement,Portion of faeces,Portion of fecal material,Portion of fecal matter,Portion of feces,Portion of guano,Portion of scat,Portionem cacas,Scat,Spoor,Spraint,Stool,Teil der fäkalien@de,Feces,feces
- Condition The experimental condition / phenotype studied according to the Experimental Factor Ontology
- Clinical treatment Clinical treatment,clinical treatment
- Group 0 name Corresponds to the control (unexposed) group for case-control studies
- Parkinson's disease (PD) patients treated with levodopa only (PD_L)
- Group 1 name Corresponds to the case (exposed) group for case-control studies
- Parkinson's disease (PD) patients treated with both levodopa and Entacapone (PD_LE)
- Group 1 definition Diagnostic criteria applied to define the specific condition / phenotype represented in the case (exposed) group
- Entacapone, one of the most common drugs distributed among patients with Parkinson’s disease, is a peripherally acting catechol-O-methyltransferase (COMT) inhibitor that is used in addition to levodopa to control symptoms
- Group 0 sample size Number of subjects in the control (unexposed) group
- 13
- Group 1 sample size Number of subjects in the case (exposed) group
- 11
Lab analysis
- Sequencing type
- 16S
- 16S variable region One or more hypervariable region(s) of the bacterial 16S gene
- V4-V5
- Sequencing platform Manufacturer and experimental platform used for quantifying microbial abundance
- Ion Torrent
Statistical Analysis
- Data transformation Data transformation applied to microbial abundance measurements prior to differential abundance testing (if any).
- relative abundances
- Statistical test
- T-Test
- Significance threshold p-value or FDR threshold used for differential abundance testing (if any)
- 0.05
- MHT correction Have statistical tests be corrected for multiple hypothesis testing (MHT)?
- Yes
- Matched on Factors on which subjects have been matched on in a case-control study
- age, sex
Alpha Diversity
- Shannon Estimator of species richness and species evenness: more weight on species richness
- unchanged
- Chao1 Abundance-based estimator of species richness
- unchanged
- Simpson Estimator of species richness and species evenness: more weight on species evenness
- unchanged
- Richness Number of species
- unchanged
Signature 1
Source: Figure 3, text
Description: ASVs that significantly differed in abundance before and after the treatment of entacapone. 108 ASVs were identified as significantly different after the treatment of entacapone. 3 ASVs that were not assigned taxonomy to the genus level had a decrease in abundance. They were removed for plotting purposes. Genus and phylum level classification of the significant ASVs are provided in the plot. Genus in bold are unique to our study when compared with Weis et al. (2019).
Abundance in Group 1: increased abundance in Parkinson's disease (PD) patients treated with both levodopa and Entacapone (PD_LE)
| NCBI | Quality Control | Links |
|---|---|---|
| Bifidobacterium | ||
| Christensenellaceae R-7 groupChristensenellaceae R-7 group | ||
| Eubacterium |
Revision editor(s): Fiddyhamma
Signature 2
Source: Figure 3, text
Description: ASVs that significantly differed in abundance before and after the treatment of entacapone. 108 ASVs were identified as significantly different after the treatment of entacapone. 3 ASVs that were not assigned taxonomy to the genus level had a decrease in abundance. They were removed for plotting purposes. Genus and phylum level classification of the significant ASVs are provided in the plot. Genus in bold are unique to our study when compared with Weis et al. (2019).
Abundance in Group 1: decreased abundance in Parkinson's disease (PD) patients treated with both levodopa and Entacapone (PD_LE)
| NCBI | Quality Control | Links |
|---|---|---|
| Sellimonas | ||
| Lactobacillus | ||
| Intestinibacter | ||
| Faecalibacterium | ||
| Dorea | ||
| Blautia |
Revision editor(s): Fiddyhamma
